Are you Dr. Tetzlaff?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Michael Tetzlaff, MD is a board certified pathologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alaska, and Illinois. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
- University of Pennsylvania Health SystemFellowship, Dermatopathology, 2009 - 2010
- University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2005 - 2009
- Baylor College of MedicineClass of 2005
Certifications & Licensure
- CA State Medical License 2020 - 2026
- IL State Medical License 2021 - 2026
- TX State Medical License 2010 - 2025
- AK State Medical License 2022 - 2024
- PA State Medical License 2005 - 2010
- American Board of Pathology Pathology - Anatomic
- American Board of Pathology Dermatopathology
Publications & Presentations
PubMed
- Silicone on the Move: Migratory Siliconoma After Retinal Surgery Report of a Case and Review of the Literature.Mitchell J Finkelstein, Tatsiana Pukhalskaya, Jeffrey A North, Thaddeus Mully, W Allen Wesche
The American Journal of Dermatopathology. 2024-12-01 - Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.Apostolia M Tsimberidou, Farah A Alayli, Kwame Okrah, Alexandra Drakaki, Danny N Khalil
The Journal of Experimental Medicine. 2024-10-07 - Dual PD-L1/SOX10 Immunohistochemistry Combined With Digital Imaging Enhances Stratification Accuracy of Patients With Metastatic Melanoma.Juan Pineda-Reyes, Sri Krishna Arudra, Phyu P Aung, Priyadharsini Nagarajan, Jonathan L Curry
The American Journal of Surgical Pathology. 2024-10-07
Press Mentions
- Lichenoid Dermatitis with Mycosis Fungoides Features Linked to Checkpoint Inhibitor TherapyJuly 28th, 2019
- Dual Neoadjuvant Checkpoint Blockade Feasible in MelanomaOctober 11th, 2018
- Neoadjuvant Combination Checkpoint Blockade Trial Yields High Response Rates for Patients with High-Risk Stage Three MelanomaOctober 8th, 2018
- Join now to see all